netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 5: Infections - Full Chapter
Notes:

Prescribing of systemic antimicrobials is 'protected'. All prescribing MUST be in accordance with the Trust Antimicrobial Policy and in conjunction with local antimicrobial guideline:

 Details...
05.03.03.02  Expand sub section  Chronic hepatitis C
Dasabuvir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
    • Check MHRA Drug Safety Updates
  • RFL:
    • For use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Elbasvir + Grazoprevir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
BlueTeq
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Glecaprevir + Pibrentasvir
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
  • RFL:
    • Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
Ledipasvir + Sofosbuvir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
BlueTeq
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Ombitasvir + paritaprevir + ritonavir
(Viekirax®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
BlueTeq
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi nd Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Ribavirin
(Hepatitis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for hepatitis B (see NICE TA for eligibility criteria) and chronic hepatitis E viraemia in immunosuppressed individuals (JFC June 2016)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See links below
    • Ribavirin is listed on this formulary for treatment of chronic hepatitis C and for immunosuppressed individuals with chronic hepatitis E viraemia
    • Ribavirin should only be prescribed by Hepatologists
  • RFL:
    • Virology/Microbiology/ID approval only.
    • Hepatology use approved for the treatment of Hepatitis C in line with NICE guidance and Hepatitis E
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per JFC and NICE TA
    • Ribavirin should only be prescribed by Hepatologists
 
Link  NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Link  NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Link  NICE TA300: Hepatitis C - peginterferon alfa and ribavirin in children and young people
Link  NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Sofosbuvir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
BlueTeq
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir + Velpatasvir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
BlueTeq
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir + Velpatasvir + Voxilaprevir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
  • RFL:
    • Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Homecare
Homecare

Traffic Light Status Information

Status Description

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf

  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary